Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Hoba Therapeutics logo — Developing Restorative Treatments for Chronic Neuropathic Pa...

Hoba Therapeutics

Developing Restorative Treatments for Chronic Neuropathic Pain and Hearing Loss

Founded 2016 Denmark Denmark 15 employees Series A Total: $27.40M Biotechnology, Health Care +1

General Information

Company Name Hoba Therapeutics
Founded Year 2016
Location Denmark Denmark +1
Founders / Decision Makers
Team member
Employees 15
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Series A
Social

Get notified when Hoba Therapeutics moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Hoba Therapeutics

Hoba Therapeutics is a Danish biotech startup focused on developing restorative treatments for chronic pain disorders and hearing loss. The company's lead compound, HB-086, targets the peripheral nervous system to reverse chronic neuropathic pain, providing a non-opioid alternative for patients. Additionally, HB-097 aims to address sensorineural hearing loss, offering both preventive and regenerative effects. Founded in 2016 and backed by Novo Holdings and Borean Innovation, Hoba Therapeutics has received notable grants, including the Accelerator grant from the European Innovation Council and the Grand Solution grant from Innovation Fund Denmark. The company's innovative approach is particularly significant given the prevalence of chronic neuropathic pain, which affects a substantial portion of the global population. With a market estimated to be valued at USD 7.6 bn, the demand for safer and more effective treatments underscores the potential impact of Hoba Therapeutics' developments. The recent €23.00M Series A investment received on 10 December 2023 has further validated the company's potential, with key investors including Eir Ventures, Indaco Venture Partners, The European Innovation Council, Medical Incubator Japan, and Export and Investment Fund. Hoba Therapeutics' strategic focus on addressing critical unmet medical needs positions it as a compelling investment opportunity in the biotechnology and pharmaceutical industries, with the potential for significant social and economic impact.

Taxonomy: Biotech, Drug Development, Neuropathic Pain, Hearing Loss, Restorative Treatments, Pharmacological Treatment, Biopharmaceuticals, Peripheral Nervous System, Chronic Pain Disorders, Neurological Disorders, Preclinical Data, Therapeutic Protein, European Innovation Council, Innovation Fund Denmark, Non-Opioid Compound

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Series A •••••• 6
Investor Investor Investor Investor Investor
•••• •••• 		10 Dec 2023
Grant •••••• 1
Investor
16 Jun 2021
Seed Round •••••• 2
Investor Investor
05 Dec 2016

FAQ About Hoba Therapeutics

Developing Restorative Treatments for Chronic Neuropathic Pain and Hearing Loss
Hoba Therapeutics was founded in 2016.
Hoba Therapeutics is headquartered in Denmark.
Hoba Therapeutics operates in the following industries: Biotechnology, Health Care, Pharmaceutical.
Hoba Therapeutics has approximately 15 employees.
Hoba Therapeutics has completed 3 funding rounds, raising a total of $27.40M. The latest funding stage is Series A.

We're actively collecting intelligence on Hoba Therapeutics.

Track Hoba Therapeutics to get notified

Don't just browse. Track.

Signal Tracker monitors Hoba Therapeutics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy

Book a demo 30 minutes